Concerns about CAR-T safety continue to be a challenge for the sector according to Bristol-Myers Squibb, which outlined plans to address such “headwinds” during a Q4 call. Bristol Myers Squibb (BMS) spoke about the chimeric antigen receptor (CAR) T-cells sector last week, explaining while the market for such therapies is expanding, growth rates are not as fast as they could be. Nadim Ahmed, president of BMS hematology department, told analysts: “Clearly, there have been some headwinds in the [CAR-T] marketplace and…